Abstract Background Chronic Obstructive Pulmonary Disease (COPD) is a chronic condition
characterised by progressive airflow limitation that is at most partially reversible. Despite the …

Background Chronic obstructive pulmonary disease (COPD) is characterised by partially
reversible airflow limitation. Many patients have little reversibility to short acting …

Background Chronic obstructive pulmonary disease (COPD) is a respiratory disease that
causes progressive symptoms of breathlessness, cough and mucus build‐up. It is the fourth …

Background: Despite the lack of reversibility, patients with chronic obstructive pulmonary
disease (COPD) often report symptomatic improvement with inhaled short acting β2 agonist …

Background Chronic obstructive pulmonary disease (COPD) is a condition associated with
high morbidity, mortality and cost to the community. Patients often report symptomatic …

Summary What is Known and Objective: Inhaled long‐acting beta‐agonists have been
licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late …

Purpose Long-acting β2-agonists (LABAs) have demonstrated efficacy in patients with
COPD in clinical trials. The purpose of this study was to assess the comparative efficacy of …

Background Long‐acting beta 2‐agonists and inhaled corticosteroids can be used as
maintenance therapy by patients with moderate to severe chronic obstructive pulmonary …

Background Inhaled short acting beta2 adrenergic agonists and ipratropium bromide are
both used in the treatment of acute exacerbations of chronic obstructive pulmonary disease …

Background Both long‐acting beta 2‐agonists (LABA) and inhaled corticosteroids (ICS)
have been recommended in guidelines for the treatment of chronic obstructive pulmonary …